ArticleFrontiers in pharmacology2025
Escalated oxycodone self-administration is associated with expression of voltage gated and calcium activated potassium channels in the mesocorticolimbic system in rats.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Can the incentive-sensitization theory of addiction incorporate addiction to opioid drugs?Psychopharmacology · 2026Review
- The relationship between duration of access to intravenous oxycodone self-administration, economic demand for oxycodone, and cognition in rats.Psychopharmacology · 2026Article
- Behavioral and transcriptomic markers of susceptibility to escalate fentanyl intake.Translational psychiatry · 2026Article
- A Challenge To The Assumption That Short- versus Long-Access Groups of Opioid Users Represent Distinct Phenotypes.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The number of individuals diagnosed with opioid use disorder (OUD) has risen steeply because of increased prescribing of opioid drugs including oxycodone for chronic pain relief. When rats given extended access to oxycodone only a subset of animals self-administers more drug over time. Identifying the molecular mechanism associated with this behavior can introduce novel ways to combat OUD. Herein, we sought to identify the alteration in the expression of voltage gated and calcium activated potassium channels after extended access to oxycodone self-administration. Methods: We used male Sprague-Dawley rats that self-administered oxycodone for 20 days according to short-access (ShA, 3 h per day) and long-access (LgA, 9 h per day) paradigms. Results: LgA rats escalated their oxycodone intake and developed into two phenotypes, named long-access high (LgA-H, escalated intake) and long-access low (LgA-L, non-escalated intake) rats, based on the quantities of oxycodone intake during the self-administration experiment. ShA rats maintained similar oxycodone intake throughout 20 days of self-administration. Rats were euthanized 2 h after the last self-administration session and their prefrontal cortex (PFC), nucleus accumbens (NAc), and hippocampus (HIP) were dissected out for gene expression analysis. Given the relationship between potassium channels and substance use disorder we performed gene expression analysis for voltage and calcium activated potassium channels. The expression of potassium channels in oxycodone self-administered rats was found to be brain region dependent. Specifically, LgA-H rats displayed increased expression of Conclusion: Our observation is of significant translational importance providing further support that targeting potassium channel can lead to development of better therapeutic approaches against OUD in humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.